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MaOBJECTIVES This study sought to evaluate the impact of arterial duct (AD) stenting in promoting catch-up growth of
hypoplastic pulmonary artery (PA) tree in congenital heart disease with duct-dependent pulmonary circulation (CHD-DPC).
BACKGROUND Signiﬁcant and balanced PA growth following AD stenting has already been consistently reported in
the literature. However, no data are so far available about the role of this approach in severe PA hypoplasia, which
signiﬁcantly impacts the risk of surgical repair.
METHODS Pre-surgical angiographic PA evaluation was performed in 45 patients with conﬂuent PAs submitted to
neonatal AD stenting as palliation of CHD-DPC. PA growth was evaluated as Nakata Index and McGoon ratio as well as
individual PA z-score changes, both in the whole population and according to the original vessel size (Nakata Index
<100 mm2/m2, Group I [n ¼ 15] vs. Nakata Index >100 mm2/m2, Group II [n ¼ 30]).
RESULTS Control angiography was performed 7.5  6.5 months (median 6 months) after duct stenting, showing sig-
niﬁcant and balanced PA growth. The Nakata Index increased from 143  73 mm2/m2 to 270  88 mm2/m2 (124  118%,
p < 0.0001); left PA z-score from 0.7  1.7 to 1.0  1.4; right PA z-score from 0.6  1.3 to 1.2  1.3 (p < 0.0001 for
both comparisons). Group I showed a greater increase of global PA growth (Nakata Index increase 227  141% vs.
72  57%, p < 0.001) as compared with Group II. Final PA size did not signiﬁcantly differ between the groups
(246  105 mm2/m2 vs. 282  78 mm2/m2, p ¼ NS).
CONCLUSIONS Percutaneous AD stenting is highly effective in promoting a signiﬁcant and balanced catch-up growth
of diminutive PAs, being therefore advisable in this subset of patients as a reliable alternative to surgical palliation.
(J Am Coll Cardiol Intv 2015;8:1626–32) © 2015 by the American College of Cardiology Foundation.A rterial duct (AD) stenting is widely consid-ered an effective palliation of congenitalheart disease with duct-dependent pulmo-
nary circulation (CHD-DPC) in high-risk patients un-
suitable for primary repair (1–6). This option may
promote signiﬁcant and more balanced pulmonary
artery (PA) growth as compared with surgical
systemic-to-pulmonary artery shunt (7–10). Howev-
er, no study has so far speciﬁcally addressed the
fate of hypoplastic PAs following AD stenting, whichm the Paediatric Cardiology and Paediatric Cardiac Surgery, A.O.R.N. “O
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The aim of this study was to evaluate the role of AD
stenting in promoting the growth potential of
diminutive PAs in patients with CHD-DPC.
METHODS
PATIENT POPULATION. Between April 2003 and
December 2014, 118 neonates and infants withspedali dei Colli,” 2nd University of Naples, Naples,
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TABLE 1 Clinical, Demographic, and Angiographic Data of Patients
Submitted to Control Angiography Following AD Stenting
N ¼ 45 (complete duct-dependent pulmonary circulation 28.9%)
Age, months 8.7  7.2 (range 3–45)
Weight, kg 6.2  2.6 (range 2.5–15)
Diagnosis
Critical PS/PA-IVS 12
ToF 12
PA-VSD 9
TV Ebstein’s anomaly 1
cTGA with critical PS/atresia 2
TA 1
TGA-VSD with critical PS/atresia 6
UVH with critical PS/atresia 1
Criss-cross heart with ToF 1
Group I (Nakata Index <100 mm2/m2, n ¼ 15)
Complete duct-dependency: 37.5%
Control angiography, months: 10  11 (median 6.5)
Critical PS/PA-IVS: 3
ToF: 5
PA-VSD: 4
TV Ebstein’s anomaly: 1
cTGA with critical PS/atresia: 2
Group II (Nakata Index >100 mm2/m2, n ¼ 30)
Complete duct-dependency: 24.1%
Control angiography, months: 8  5 (median 6)
Critical PS/PA-IVS: 9
ToF: 7
PA-VSD: 5
TA: 1
TGA-VSD with critical PS/atresia: 6
UVH with critical PS/atresia: 1
Criss-cross heart with ToF: 1
Values are n unless otherwise indicated.
AD ¼ arterial duct; cTGA ¼ corrected transposition of great arteries; PA-IVS ¼ pulmonary valve
atresia with intact ventricular septum; PA-VSD ¼ pulmonary valve atresia with ventricular septal
defect; PS ¼ pulmonary valve stenosis; TA ¼ tricuspid valve atresia; TGA ¼ transposition of great
arteries; ToF ¼ tetralogy of Fallot; TV ¼ tricuspid valve; UVH ¼ univentricular heart;
VSD ¼ ventricular septal defect.
AB BR E V I A T I O N S
AND ACRONYM S
AD = arterial duct
CHD-DPC = congenital heart
disease with duct-dependent
pulmonary circulation
PA = pulmonary artery
PBF = pulmonary blood ﬂow
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1627CHD-DPC underwent successful AD stenting at our
institution as a cost-effective alternative to surgical
palliation. Mean hospital stay for AD stenting was 12
days in a regular ward compared with 10 days (3 days
in a post-surgical intensive care unit and 7 in a regular
ward) for a surgical shunt, resulting in a similar global
economic impact (V9,823 vs. V11,090). Among these
patients, 45 needed just a short time of support to
pulmonary circulation, 17 are still in follow-up before
planned surgical repair, and 4 died before hospital
discharge. The remaining 52 patients needed surgical
repair over a mid-term follow-up and were submitted
to control cardiac catheterization 7.5  6.5 months
(range 2 to 45 months, median 6 months) after the
initial palliation. Seven patients were excluded from
the analysis because the stented duct supplied
disconnected PAs. The demographic and clinical data
of the remaining 45 patients are reported in Table 1.
At the time of AD stenting, 39 patients showed
biventricular physiology, and the remaining 6 pa-
tients were supposed to be candidates for Fontan
track. Thirteen patients had complete duct de-
pendency of the pulmonary circulation due to trivial
or absent additional pulmonary blood ﬂow (PBF)
(28.9%), whereas the remaining 32 patients showed
mild, but clinically insigniﬁcant, accessory PBF. Eight
of the 12 patients with pulmonary valve atresia with
intact ventricular septum and none of the patients
with pulmonary valve atresia with ventricular septal
defect had been submitted to pulmonary valve
perforation at the time of AD stenting. No patient
showed hemodynamic signiﬁcant aortopulmonary
collaterals at control angiography. At the time of AD
stenting, 15 patients showed very hypoplastic PAs
(Nakata Index <100 mm2/m2, range 46 to 100, median
79 mm2/m2; Group I), whereas the remaining 30 pa-
tients had normal or mildly reductive PAs (Nakata
Index >100 mm2/m2, range 110 to 399, median 164
mm2/m2; Group II). No difference was found between
groups in terms of intracardiac anatomy, as well as
complete duct dependency of the pulmonary circu-
lation (Table 1).
INTERVENTIONAL PROCEDURE. AD stenting was
performed under general anesthesia following a pre-
viously described protocol, with the aim of covering
the entire AD length (4–6). Mean prostaglandin
dosage at the time of AD stenting was 0.02 g/kg/min,
but prostaglandin infusion had been stopped some
few hours before the procedure. The stent size was
individually chosen on the basis of patient size,
ductal anatomy, and expected time for which pallia-
tion was needed. However, it was usually about 25%
smaller than the planned surgical shunt in the beliefthat it acted more as a central shunt than a
Blalock-Taussig shunt. After stent deploy-
ment, repeat aortic angiograms were per-
formed in multiple views to exclude
incomplete coverage of the duct as well as to
evaluate the PA size and any potential stent-
related PA stenosis. After the procedure,
long-term acetylsalicylic acid treatment was
planned at a dose of 3 to 5 mg/kg/day.ANGIOGRAPHIC MEASUREMENTS. Control cardiac
catheterization was scheduled whenever oxygen
saturation was consistently reduced over at least 2
follow-up visits or before scheduled surgical repair.
Pulmonary angiography was performed in right
anterior oblique and four-chamber views (Figure 1),
measuring individual PAs at the site of their ﬁrst
branching point. The diameter of the descending
FIGURE 1 PA Angiography Before and After AD Stenting
Pulmonary artery (PA) angiography in the 4-chamber view before (A) and 5 months
after arterial duct (AD) stenting (B) in a newborn with originally severe PA hypoplasia
(Nakata Index increase from 90 to 190 mm2/m2, þ111%). The asterisk indicates the
stented arterial duct. Ao ¼ descending aorta; LPA ¼ left pulmonary artery; RPA ¼ right
pulmonary artery.
TABLE 2 PA Growth
to PBF Physiology
Nakata Index, mm2/m2
McGoon ratio
LPA, mm
z-score
LPA/Ao diameter r
Right PA, mm
z-score
RPA/Ao diameter r
LPA/RPA diameter ra
PA stenosis
Complete duct-depend
PBF (n ¼ 13)
Nakata Index, mm2/m
McGoon ratio
Multiple PBF sources (n
Nakata Index, mm2/m
McGoon ratio
Values are mean  SD unle
AD ¼ arterial duct; Ao
circulation; LPA ¼ left pul
pulmonary artery.
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1628aorta was measured at the diaphragm level. All the
values were obtained during ventricular systole and,
if possible, from the same angiographic frame using
the angiographic catheter as a reference. Indexed PA
cross-sectional area (Nakata Index) (11) and ratio
of the sum of diameters of both PAs to diameter
of the descending aorta (McGoon ratio) (12) were
considered indicative of global vessel growth.
Normative diameters of main PAs against bodyFollowing AD Stenting in the Whole Population and According
Pre-Stent Post-Stent % Change p Value
Interaction
Term
(p Value)
143  73 270  88 124  118 0.0001
1.4  0.3 2.0  0.5 46  36 0.0001
3.9  1.2 6.9  1.8 85  51 0.0001
0.7  1.7 1.0  1.4 0.0001
atio 0.7  0.2 1.0  0.2 0.0001
4.1  1.1 7.8  2.1 95  52 0.0001
0.6  1.3 1.2  1.3 0.0001
atio 0.8  0.2 1.1  0.4 0.0001
tio 1.0  0.2 0.9  0.3 5  30 NS
11/45 (24.4%)
ent
2 146  63 232  94 76  91 0.0001 0.055
1.4  0.3 1.9  0.3 37  30 0.0001 NS
¼ 32)
2 143  79 289  82 145  125 0.0001*
1.5  0.3 2.1  0.5 48  39 0.0001*
ss otherwise indicated. *p ¼ NS versus complete duct-dependent PBF.
¼ aorta; CHD-DPC ¼ congenital heart disease with duct-dependent pulmonary
monary artery; PA ¼ pulmonary artery; PBF ¼ pulmonary blood ﬂow; RPA ¼ rightsurface area (z-scores) were obtained from Internet
nomograms and were deemed an index of individual
PA growth. Finally, the left-to-right PA diameter ratio
was considered an expression of balanced vascular
growth.
STATISTICAL ANALYSIS. All analyses were per-
formed using SPSS for Windows version 13.0 (SPSS,
Chicago, Illinois). Results are expressed as mean 
SD. Comparisons were performed using paired and
unpaired Student t tests as well as the chi-square test.
Changes between pre- and post-stenting were
analyzed as repeated measures analysis of variance,
with the group by pre–post interaction term included
to assess the time effect on the growth changes
between the groups. Signiﬁcance was deﬁned as a
p value <0.05.
RESULTS
AD patency was established with stents dilated to a
mean diameter of 3.6  0.4 mm (range 3.2 to 4.5 mm,
median 3.5 mm). The mean stent length was 13.4 
4.0 mm (range 8 to 24 mm, median 12 mm). AD sta-
bilization was achieved using a single stent in the
majority of patients, whereas 12 patients received 2
stents, 1 patient received 3 stents, and 1 patient
received 4 stents. Ductal stenting resulted in a sig-
niﬁcant increase in oxygen saturation, from 81  10%
to 89  7% (p < 0.001). No signiﬁcant difference was
found between the groups in terms of ﬁnal duct size
(3.4  0.4 mm vs. 3.7  0.4 mm, p ¼ NS) and length
(13.3  5.0 mm vs. 16.5  4.5 mm, p ¼ NS), as well as
O2 saturation (86  8% vs. 90  7%, p ¼ NS). Ductal
origin was in the typical position from the aortic
isthmus/upper thoracic aorta in 35 patients, whereas
it was vertical in 10 patients, without any difference
between the groups (26.7% vs. 20.0%, p ¼ NS). Con-
trol angiography was performed after a median time
of 6 months from the procedure, without a signiﬁcant
difference between groups (Table 1). Pre-surgical
angiographic evaluation showed signiﬁcant and
balanced PA growth in the whole population, without
any difference between newborns with complete
duct-dependent pulmonary circulation versus multi-
ple PBF sources (Table 2). However, Group I showed a
better catch-up growth of the PA tree as compared
with the group with mildly reductive PAs, without a
signiﬁcant difference between the groups in terms of
ﬁnal Nakata Index value at control angiography
(Table 3, Figure 2). No signiﬁcant difference was
found either in the whole population or in the sub-
groups according to either cardiac anatomy or duct
morphology and size/length. Mild-to-moderate
TABLE 3 PA Growth According to Vessel Size at the Time of AD Stenting
Pre-Stent Post-Stent p Value
Interaction
Term (p Value)
Group I (Nakata Index <100 mm2/m2, n ¼ 15)
Nakata Index, mm2/m2 78  17 246  105 0.0001
NS vs. Group II
0.03
% change 227  141 0.0001 vs. Group II
McGoon ratio 1.2  0.2 2.0  0.4 0.0001
NS vs. Group II
NS
% change 64  36 NS vs. Group II
LPA size, mm 3.1  1.3 6.4  2.3 0.0001
NS vs. Group II
NS
LPA z-score 2.1  1.8 0.5  1.8 0.0001
0.01 vs. Group II
0.01
% change 110  56 0.01 vs. Group II
LPA/Ao diameter ratio 0.6  0.2 0.9  0.3 0.0001
NS vs. Group II
NS
RPA size, mm 3.4  1.1 7.2  2.7 0.0001
NS vs. Group II
NS
RPA z-score 1.7  1.4 0.8  1.8 0.0001
NS vs. Group II
NS
% change 112  70 NS vs. Group II
RPA/Ao diameter ratio 0.7  0.2 1.0  0.4 0.0001
NS vs. Group II
NS
LPA/RPA diameter ratio 0.9  0.2 1.0  0.4 NS NS
% change 5  38 NS vs. Group II
PA stenosis 4/15 (26.7%) NS vs. Group II
Group II (Nakata Index >100 mm2/m2, n ¼ 30)
Nakata Index, mm2/m2 176  69 282  78 0.0001
% change 72  57
McGoon ratio 1.5  0.3 2.1  0.4 0.0001
% change 43  36
LPA, mm 4.3  1.0 7.2  1.5 0.0001
z-score 0.0  1.3 1.3  1.3 0.0001
% change 72  44
LPA/Ao diameter ratio 0.8  0.2 1.0  0.2 0.0001
RPA, mm 4.4  0.9 8.1  1.7 0.0001
z-score 0.1  0.9 1.4  1.0 0.0001
% change 86  39
RPA/Ao diameter ratio 0.8  0.2 1.1  0.3 0.0001
LPA/RPA diameter ratio 1.0  0.2 0.9  0.2 NS
% change 7  17
PA stenosis 7/30 (23.3%)
Values are mean  SD.
Abbreviations as in Tables 1 and 2.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 2 , 2 0 1 5 Santoro et al.
O C T O B E R 2 0 1 5 : 1 6 2 6 – 3 2 Growth of Hypoplastic Pulmonary Arteries After Arterial Duct Stenting
1629stenosis at the site of duct insertion was imaged in
24.4% of the patients, without a signiﬁcant difference
between the groups (26.7% vs. 23.3%, p ¼ NS). How-
ever, this complication was easily addressed without
incremental risk at the time of surgical repair.
DISCUSSION
Failure to achieve adequate PA growth is a major
obstacle to undergoing surgical repair for patients
with cyanotic congenital heart disease (13–15).
Indeed, PA hypoplasia was reported as a signiﬁcant
procedure-dependent factor in determining the
Comprehensive Aristotle Score, either for surgical
palliation or repair of CHD-DPC (16). Therefore, a
major aim of neonatal palliation is to promote sig-
niﬁcant and balanced growth of the PA tree.
Systemic-to-pulmonary shunt has been consistently
found to allow signiﬁcant vessel growth (17–21),
although scant data are so far available in the case of
hypoplastic PAs (22–24). Over time, AD stenting has
gained wide acceptance as a reliable alternative to
surgical palliation in patients with CHD-DPC (1–8).
This option may be considered cost effective with
respect to a surgical shunt in high-risk patients un-
suitable for primary repair or whenever short-term
PBF support is anticipated (4–6,25,26). In addition,
duct patency has become an effective tool to promote
signiﬁcant and more balanced PA growth as compared
with surgical palliation (1,5–10). To date, scant data
on global and individual growth of diminutive PAs
resulting from AD stenting are available in the liter-
ature. However, this anatomic arrangement is widely
considered as a relative contraindication to this
approach; in this case, a surgical central shunt (27) or
percutaneous right ventricular outﬂow tract stenting
(15,28) is still advocated as better therapeutic options.
In our opinion, AD stenting confers most of the
procedural and hemodynamic advantages of both
options, being at lower risk than surgical palliation
(5,6,9) and resulting in continuous (as with a surgical
shunt) and balanced (as with right ventricular outﬂow
tract stenting) PBF. In addition, conforming the stent
to the size and angulations of the main PAs may
theoretically maximize PA growth potential.
In this study, AD stenting conﬁrmed its efﬁcacy in
promoting the signiﬁcant and uniform PA growth
already previously reported (1,7–10). Despite a trend
toward better PA growth in the case of multiple PBF
sources, this favorable effect was recorded even in
newborns with AD as a single source of pulmonary
ﬂow, possibly due to optimal orientation of ductal
ﬂow. In addition, a better impact of AD stenting on
growth potential of reductive PAs was found. In thishigher-risk population, AD stenting allowed a catch-
up PA growth compared with patients with mildly
reductive PAs, despite similar demographic, clinical,
and hemodynamic characteristics at the time of the
procedure, as well as a similar diameter and length of
the stented AD, and the same span of percutaneous
palliation. Indeed, the “hypoplastic” group showed a
faster catch-up growth, with a signiﬁcantly higher
percentage increase of the Nakata Index at follow-up
evaluation. The ﬁnal absolute PA size did not signif-
icantly differ between the groups, and also the PA
tree of patients with originally diminutive branches
achieved the normal range, thus decreasing their risk
FIGURE 2 Nakata Index Changes Following AD Stenting and the Time Effect on PA Growth
(A) Nakata Index changes following AD stenting in severely hypoplastic (Group I) as compared with mildly reductive (Group II) PAs. (B) Time
effect on the PA growth in the 2 groups. Left (C) and right (D) PA z-scores increase after AD stenting. Abbreviations as in Figure 1.
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1630proﬁle for surgical repair. Finally, the growth of both
PA branches in this high-risk population was balanced
without any signiﬁcant difference in terms of focal
stenosis at the site of duct insertion as compared with
the originally normal-sized PA group.
Thus, AD stenting should be considered as the ﬁrst-
choice palliative option in neonates with CHD-DPC
and diminutive PAs, either those likely to achieve
biventricular repair or destined to the Fontan circu-
lation. In this latter subset, this approach should be
even more advisable than surgical palliation in that it
promotes similar, but more uniform, growth of the
pulmonary vascular tree than a conventional surgical
shunt (22,23), thereby hopefully favorably inﬂuencing
long-term outcome of univentricular physiology.
STUDY LIMITATIONS. The study aims of comparing the
mid-term effect of AD stenting in CHD-DPC with very hy-
poplastic versusmildly reductive PAs might be hampered
by some theoretical limitations. First, the patient popula-
tion is quite small, thereby precluding any reliable multi-
factorial analysis on the impact of patient’s demographic
proﬁle, ductal anatomy, size, and length, as well as
accessory PBF, on pulmonary vascular development.
However, in this era of early surgical repair, this approachshould be viewed as a short-term palliation, thus making
less inﬂuential these variables on PA growth promotion.
Second, the retrospective and nonrandomized nature of
enrolment may have introduced potentially signiﬁcant
selection biases in evaluating the impact of this palliative
option in the2different anatomic settings.However, there
was no signiﬁcant difference between the groups in terms
of demographic data or pre-procedural anatomy and
physiology (complete vs. partial pulmonary duct-
dependency, “typical” vs. “vertical” ductal orientation,
size and length of stented AD), and this option produced
similar oxygen saturation over the study period. Third,
this study did not evaluate the effect of surgical shunt or
right ventricular outﬂow stenting in a matched popula-
tion, thereby precluding any interpretation about the best
option in this anatomic setting. However, our study did
not aim to compare AD stenting versus other palliative
options, but rather to evaluate the potentiality of this
approach in an anatomically “borderline” population.
CONCLUSIONS
Percutaneous AD stenting with highly ﬂexible bare-
metal coronary stents may be considered an effective
PERSPECTIVES
WHAT IS KNOWN? PA growth is a major aim of palliation of
CHD-DPC unsuitable for primary repair. AD stenting is nowadays
not considered optimal palliation in the case of hypoplastic PAs,
with surgical shunt or right ventricular out-ﬂow tract stenting
being advised in this setting.
WHAT IS NEW? This study shows that AD stenting is highly
effective in promoting a signiﬁcant catch-up growth of very
diminutive PAs, signiﬁcantly better than in the case of mildly
reductive PAs. Thus, this option could be more strongly proposed
as the ﬁrst-choice approach in this subset of patients in view of
a lower-risk corrective surgical repair, and so modifying the
selection strategy of interventional palliation.
WHAT IS NEXT? Further studies enrolling larger populations
might better clarify the role of this approach on pulmonary
vascular development in terms of impact of patient’s demo-
graphic proﬁle, ductal anatomy, size and length, as well as
accessory PBF.
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1631tool in promoting signiﬁcant and balanced PA growth
in CHD-DPC over a mid-term follow-up. It seems
highly effective in very diminutive PAs, thus resulting
in a signiﬁcant catch-up recruitment of pulmonary
vessel growth potential. Thus, this option could be
more strongly proposed as the ﬁrst-choice approach in
this subset of patients in view of lower-risk corrective
surgical repair, and somodifying the selection strategy
of interventional palliation.
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